Improved retention associated with community-based accompaniment for antiretroviral therapy delivery in rural Rwanda

Clinical Infectious Diseases

Volumn 56, Issue 9, 2013, Pages 1319-1326

  Franke, Molly F ^a,c   Kaigamba, Felix ^b   Socci, Adrienne R ^c   Hakizamungu, Massudi ^c   Patel, Anita ^c   Bagiruwigize, Emmanuel ^b   Niyigena, Peter ^c   Walker, Kelly D C ^c   Epino, Henry ^c,e,f   Binagwaho, Agnes ^a,d   Mukherjee, Joia ^a,c,e   Farmer, Paul E ^a,c,e   Rich, Michael L ^c,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Ruhengeri Hospital   (Rwanda)

^c PARTNERS IN HEALTH   (United States)

^d Ministry of Health of Rwanda   (Rwanda)

^e Brigham and Women's Hospital   (United Kingdom)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Africa; community health workers; HIV; nutrition; retention

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMMUNITY CARE; DEATH; DEPRESSION; FEMALE; FOLLOW UP; FOOD INSECURITY; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RURAL AREA; RWANDA; SOCIAL SUPPORT; TREATMENT DURATION; TUBERCULOSIS; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RURAL POPULATION; RWANDA; SOCIAL SUPPORT; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84875990572     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1193     Document Type: Article

References (41)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS at 30: nations at the crossroads. 2011. Available at: http://www.unaids. org/unaids-resources/ aidsat30/aids-at-30.pdf. Accessed 1 November 2011.
2. Franke MF, Murray MB, Muñoz M, et al. Food insufficiency is a risk factor for suboptimal antiretroviral therapy adherence among HIVinfected adults in urban Peru. AIDS Behav 2011; 15:1483-9.
3. Weiser SD, Frongillo EA, Ragland K, et al. Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med 2009; 24:14-20.
4. Tuller DM, Bangsberg DR, Senkungu J, et al. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav 2010; 14:778-84.
5. Charurat M, Oyegunle M, Benjamin R, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One 2010; 5: e10584.
6. Carrico AW, Riley ED, Johnson MO, et al. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization. J Acquir Immune Defic Syndr 2011; 56:146-50.
7. Kacanek D, Jacobson DL, Spiegelman D, et al. Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the Nutrition for Healthy Living study. J Acquir Immune Defic Syndr 2010; 53:266-72.
8. Harris J, Pillinger M, Fromstein D, et al. Risk factors for medication non-adherence in an HIV infected population in the Dominican Republic. AIDS Behav 2011; 15:1410-5.
9. Dlamini PS, Wantland D, Makoae LN, et al. HIV stigma and missed medications in HIV-positive people in five African countries. AIDS Patient Care STDS 2009; 23:377-87.
10. Shin S, Muñoz M, Espiritu B, et al. Psychosocial impact of poverty on antiretroviral nonadherence among HIV-TB coinfected patients in Lima, Peru. J Int Assoc Physicians AIDS Care 2008; 7:74-81.
11. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.
12. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15(suppl 1):1-15.
13. Muñoz M, Finnegan K, Zeladita J, et al. Community-based DOTHAART accompaniment in an urban resource-poor setting. AIDS Behav 2010; 14:721-30.
14. Bärnighausen T, Chaiyachati K, Chimbindi N, et al. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis 2011; 11:942-51.
15. Koenig SP, Léandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS 2004; 18(suppl 3):S21-5. (Pubitemid 39037455)
16. Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004; 38:S429-36. (Pubitemid 38738542)
17. Rich ML, Miller AC, Niyigena P, et al. Excellent clinical outcomes and high retention in care among adults in a community-based HIV treatment program in rural Rwanda. J Acquir Immune Defic Syndr 2012; 59:e35-42.
18. Lowrance DW, Ndamage F, Kayirangwa E, et al. Adult clinical and immunologic outcomes of the national antiretroviral treatment program in Rwanda during 2004-2005. J Acquir Immune Defic Syndr 2009; 52:49-55.
19. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL). A measure of primary symptom dimensions. Mod Probl Pharmacopsychiatry 1974; 7: 79-110.
20. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 1974; 19:1-15.
21. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997; 6:481-93. (Pubitemid 27431704)
22. Broadhead WE, Gehlbach SH, de Gruy FV, Kaplan BH. The Duke-UNC Functional Social Support Questionnaire. Measurement of social support in family medicine patients. Med Care 1988; 26:709-23.
23. Epino HM, Rich ML, Kaigamba F, et al. Reliability and construct validity of three health-related self-report scales in HIV-positive adults in rural Rwanda. AIDS Care 2012; 24:1576-83.
24. Coates J, Swindale A, Bilinsky P. Household Food Insecurity Access Scale (HFIAS) for measurement of household food access: indicator guide (v. 3). Washington, DC: Food and Nutrition Technical Assistance Project, Academy for Educational Development; 2007.
25. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2011. Available at: http://www.aidsinfo.nih.gov/ContentFiles/. Accessed 23 March 2011.
26. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005; 162:199-200. (Pubitemid 41373523)
27. Schafer J. Analysis of incomplete multivariate data. New York: Chapman and Hall; 1997.
28. Fatti G, Meintjes G, Shea J, Eley B, Grimwood A. Improved survival and antiretroviral treatment outcomes in adults receiving communitybased adherence support: five-year results from a multicentre cohort study in South Africa. J Acquir Immune Defic Syndr 2012; 61:e50-8.
29. Grimwood A, Fatti G, Mothibi E, Malahlela M, Shea J, Eley B. Community adherence support improves programme retention in children on antiretroviral treatment: a multicentre cohort study in South Africa. J Int AIDS Soc 2012; 15:173-81.
30. Pearson CR, Micek MA, Simoni JM, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr 2007; 46:238-44. (Pubitemid 47482621)
31. Center for Treatment and Research on AIDS. Report on the evaluation of clinical and immunologic outcomes from the national antiretroviral treatment program in Rwanda, 2004-2005. Kigali, Rwanda: Ministry of Health; 2008.
32. Cambiano V, Lampe FC, Rodger AJ, et al. Long-term trends in adherence to antiretroviral therapy from start of HAART. AIDS 2010; 24:1153-62.
33. Do NT, Phiri K, Bussmann H, et al. Psychosocial factors affecting medication adherence among HIV-1 infected adults receiving combination antiretroviral therapy (cART) in Botswana. AIDS Res Hum Retroviruses 2010; 26:685-91.
34. Bastard M, Koita Fall MB, Lanièce I, et al. Revisiting long-term adherence to HAART in Senegal using latent class analysis. J Acquir Immune Defic Syndr 2011; 57:55-61.
35. Chang LW, Kagaayi J, Nakigozi G, et al. Effect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial. PLoS One 2010; 5:e10923.
36. Hegazi A, Bailey RL, Ahadzie B, Alabi A, Peterson K. Literacy, education and adherence to antiretroviral therapy in The Gambia. AIDS Care 2010; 22:1340-5.
37. Wagner GJ, Goggin K, Remien RH, et al. A closer look at depression and its relationship to HIV antiretroviral adherence. Ann Behav Med 2011; 42:352-60.
38. Partners In Health. The PIH guide to the community-based treatment of HIV in resource-poor settings. Second. Boston, MA: Partners In Health/Program in Infectious Disease and Social Change/Division of Social Medicine and Health Inequalities, Brigham and Women's Hospital/Harvard Medical School; 2006.
39. Riley ED, Neilands TB, Moore K, Cohen J, Bangsberg DR, Havlir D. Social, structural and behavioral determinants of overall health status in a cohort of homeless and unstably housed HIV-infected men. PLoS One 2012; 7:e35207.
40. Decroo T, Telfer B, Biot M, et al. Distribution of antiretroviral treatment through self-forming groups of patients in Tete province, Mozambique. J Acquir Immune Defic Syndr 2011; 56:e39-44 .
41. Kim S, Hughes MD, Hammer SM, et al. Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. AIDS Res Hum Retroviruses 2000; 16:645-53. (Pubitemid 30235990)